

Title: Sex differences between females and males in antipsychotic medication efficacy and adverse effects in the treatment of schizophrenia

Short title: Sex differences and antipsychotics

Journal: CNS Drugs

Authors:

Megan Galbally^{1,2} ORCID [0000-0003-3909-1918](https://orcid.org/0000-0003-3909-1918)

Karen Wynter^{1,3} ORCID [0000-0003-4620-7691](https://orcid.org/0000-0003-4620-7691)

Dan Siskind^{4,5} ORCID [0000-0002-2072-9216](https://orcid.org/0000-0002-2072-9216)

Christoph U. Correll^{6,7,8,9} ORCID [0000-0002-7254-5646](https://orcid.org/0000-0002-7254-5646)

Korinne Northwood^{4,5} ORCID [0000-0001-6268-547X](https://orcid.org/0000-0001-6268-547X)

Susanna Every-Palmer¹⁰ ORCID [0000-0001-6455-9741](https://orcid.org/0000-0001-6455-9741)

Affiliations:

1. School of Clinical Sciences, Monash University, Australia
2. Health Futures Institute, Murdoch University, Australia
3. Faculty of Health, Deakin University, Australia
4. Faculty of Medicine, The University of Queensland, Brisbane, Australia
5. Metro South Addiction and Mental Health Hospital and Health Service, Brisbane, Australia
6. Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA
7. Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
8. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany
9. German Center for Mental Health (DZPG), partner site Berlin, Germany
10. Department of Psychological Medicine, University of Otago Wellington, New Zealand

Address Correspondence to: Professor Megan Galbally, megan.galbally@monash.edu

Supplementary Table 6: Changes in weight/Body Mass Index (BMI) (Baseline to End of phase) by sex, within each treatment group

		Total n	Females			Males			p^1	d
			Mean	SD	n	Mean	SD	n		
Olanzapine	Change in weight from baseline	241	10.12	16.333	68	10.05	16.529	173	0.979	-0.002
	% weight gain from baseline	241	6.02	11.016	68	5.7	9.208	173	0.961	0.000
	Change in BMI from baseline	239	1.87	2.784	66	4.49	2.436	173	0.239	-0.059
Perphenazine	Change in weight from baseline	192	1.28	15.059	46	-2.46	17.797	146	0.138	-0.107
	% weight gain from baseline	192	1.36	9.528	46	-0.46	8.964	146	0.134	-0.108
	Change in BMI from baseline	190	0.28	2.445	46	-0.3	2.571	144	0.138	-0.108
Quetiapine	Change in weight from baseline	231	3.18	14.037	49	1.1	16.975	182	0.138	-0.107
	% weight gain from baseline	231	2.04	8.293	49	0.84	8.776	231	0.134	-0.108
	Change in BMI from baseline	231	0.55	2.4	49	0.016	2.428	182	0.138	-0.108
Risperidone	Change in weight from baseline	246	-3.1	18.433	67	2.22	15.766	179	0.375	-0.058
	% weight gain from baseline	246	-0.96	7.255	67	1.42	7.944	179	0.379	-0.058
	Change in BMI from baseline	246	-0.47	2.997	67	0.35	2.359	179	0.299	-0.068
Ziprasidone	Change in weight from baseline	118	-0.29	17.335	35	-2.95	13.729	83	0.083	0.111
	% weight gain from baseline	118	-0.68	7.75	35	-1.55	7.109	83	0.075	0.114
	Change in BMI from baseline	117	-0.11	2.998	34	-0.45	2.02	83	0.085	0.110

BMI: body mass index; SD: standard deviation

¹ p -values and effect sizes associated with Mann-Whitney U tests